| Uppsala, Sweden, January 15, 2008
New CEO at Gyros AB
Lars Eric Utterman takes over as acting CEO after Jan Würtz.
|
| Jan Würtz has worked diligently to implement
the strategies set by the board during his years as CEO. A significant
and growing market for Gyros’ products is now emerging. In
the phase of change that lays ahead a CEO with a different profile
is required.
Until a permanent CEO is assigned Lars Eric Utterman will serve
as acting CEO.
Utterman has extensive experience in the Biotech and Life Science
industry. In particular, his skills in the area of marketing and
sales of capital equipment for life science research will be an
important asset at Gyros.
Lars Eric Utterman is well renowned in the industry. His informal
and enthusiastic way of involvement is known to bring energy into
organisations and processes.
The board and the major investors are confident about Gyros’
technology and its employee’s ability to turn Gyros into a
successful company.
Uppsala 2008-01-15
Board of Directors
Gyros AB
For inquires, please contact Per Carendi, Chairman of the Board,
at +46 (0) 708 11 21 11 or Lars Eric Utterman, acting CEO, at +49
151 15 64 32 87.
|
About Gyros AB
Gyros is the leader in the miniaturization and integration of laboratory
applications through its proprietary microfluidics platform, Gyrolab
CD (compact disc) microlaboratory. Gyros delivers simple to use,
precisely controlled solutions for processing hundreds of samples
in parallel, generating more information from less sample and improving
lab productivity and efficiency.
Application-specific microlaboratories use a modular design offering
the potential to run different applications on a single instrument
and to create customized solutions. The company is currently focused
on two market segments: quantitative protein analysis for research,
drug discovery and development applications; and, in vitro diagnostics
for medical applications. Gyros has 50 employees working at its
headquarters and European sales office in Uppsala, Sweden and its
sales office in the USA.
For further information, visit www.gyros.com
------------------------------------------------------------------------------------------------
Statements in this press release that are not strictly historical
may be forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be
duly noted that a variety of factors could cause actual results
and experiences to differ materially from what is herein expressed.
Risks and uncertainties include, but are not limited to, risks associated
with the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully develop,
adapt, produce or commercialize products, the ability to identify
and develop new products and to differentiate products from those
of competitors, as well as various legal hazards.
------------------------------------------------------------------------------------------------
|
